Business Description
Apollomics Inc
NAICS : 541714
SIC : 2834
ISIN : KYG0411D1079
Share Class Description:
APLM: Ordinary Shares - Class ADescription
Apollomics Inc is an innovative clinical-stage biopharmaceutical company focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. The company lead programs include vebreltinib (APL-101), a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other advanced tumors with c-Met alterations, and uproleselan (APL-106), a specific E-Selectin antagonist that has the potential to be used adjunctively with standard chemotherapy to treat acute myeloid leukemia.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 5.49 | |||||
| Equity-to-Asset | 0.6 | |||||
| Debt-to-Equity | 0.23 | |||||
| Debt-to-EBITDA | -0.08 | |||||
| Piotroski F-Score | 2/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | -530.1 | |||||
| 3-Year EPS without NRI Growth Rate | -533.5 | |||||
| 3-Year FCF Growth Rate | -367.1 | |||||
| Future 3-5Y EPS without NRI Growth Rate | 78.73 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 31.37 | |||||
| 9-Day RSI | 37.05 | |||||
| 14-Day RSI | 39.43 | |||||
| 6-1 Month Momentum % | -46.04 | |||||
| 12-1 Month Momentum % | -88.05 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 2.25 | |||||
| Quick Ratio | 2.25 | |||||
| Cash Ratio | 2.05 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | 77.7 | |||||
| Shareholder Yield % | -42.87 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -145.53 | |||||
| ROA % | -106.2 | |||||
| ROIC % | -359.13 | |||||
| ROC (Joel Greenblatt) % | -5681.32 | |||||
| ROCE % | -141.05 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 0.43 | |||||
| Price-to-Tangible-Book | 0.56 | |||||
| EV-to-EBIT | 0.21 | |||||
| EV-to-Forward-EBIT | -4.28 | |||||
| EV-to-EBITDA | 0.22 | |||||
| EV-to-FCF | 0.35 | |||||
| Price-to-Net-Current-Asset-Value | 0.61 | |||||
| Price-to-Net-Cash | 0.74 | |||||
| Earnings Yield (Greenblatt) % | 476.19 | |||||
| FCF Yield % | -387.02 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:APLM
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Apollomics Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -15 | ||
| Beta | 0 | ||
| Volatility % | 69.64 | ||
| 14-Day RSI | 39.43 | ||
| 14-Day ATR ($) | 2.99052 | ||
| 20-Day SMA ($) | 11.73435 | ||
| 12-1 Month Momentum % | -88.05 | ||
| 52-Week Range ($) | 7.55 - 116 | ||
| Shares Outstanding (Mil) | 1.1 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Apollomics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Apollomics Inc Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Apollomics Inc Frequently Asked Questions
What is Apollomics Inc(APLM)'s stock price today?
The current price of APLM is $8.16. The 52 week high of APLM is $116.00 and 52 week low is $7.55.
When is next earnings date of Apollomics Inc(APLM)?
The next earnings date of Apollomics Inc(APLM) is 2025-03-28 Est..
Does Apollomics Inc(APLM) pay dividends? If so, how much?
Apollomics Inc(APLM) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers